Café des sciences #93 : « Metabo-Oncology : at the Crossroads of Cancer and Obesity - An Emerging Field of Cancer Research and Treatment »

, Lire cette page en français , Share

Café des Sciences #93 : James Shanahan, co-founder in SynDevRx, Inc., will present the metabo-oncology used in the cancer treatments.

- When : Tuesday, September 18
- Where : CIC Cambridge, 101 Main Street Cambridge MA 02142 (Lookout kitchen, floor 15th)
- Registration
- Presentation in French


James Shanahan is the co-Founder, Vice President of Business Development and Director of SynDevrx.
Jim has nearly two decades of business development experience with biotech and technology companies.
In 1998 Jim co-founded JAM Technologies, a fabless semiconductor company serving the consumer electronics and specialty electronics markets, where he served as vice president of corporate development (1998-2006) and on the board of directors (1998-2003). There, he focused on fundraising, executing licensing transactions and forming strategic co-development partnerships, including with AKM, Intel and Apple. Since 2014, he has served as a consultant to Ariana Pharmaceuticals, which provides healthcare data analytics to the pharmaceutical and biotech markets.
Jim is a founding member of the French-American Biotech Springboard, a professional association working under the auspices of the French-American Chamber of Commerce. He is also an active coach and mentor to numerous startups in the Boston area. Jim has three issued patents, studied engineering and French at the University of Massachusetts Amherst and attended L’Universite Catholique (Angers, France) in 1983.


The metabo-oncology is an area of research focused on the connection between cancer and metabolic dysfunction (which is typical in overweight and obese people).
Today, there are no therapies that specifically address the myriad factors that accelerate tumor growth in overweight and obese patients with cancer.
SynDevRx is filling that gap, thus giving hope to the thousands of patients for whom traditional treatments don’t work. This company believes that by correcting the underlying metabolic dysfunction, it can reduce the tumor-stimulating hormones and inflammation while also directly treating the tumor in its target patient population.
This company look forward to meeting the challenges of bringing metabo-oncology products to the market and to improving clinical outcomes for the millions of cancer patients with underlying metabolic dysfunction worldwide.


6:00pm: Welcome
6:30: Startup pitches (3min pitch and 1min Q&A)
6:30: Presentation and Questions&Answers
7:00: Networking


Partners of the Café des Sciences

For more information :